{"disease":{"id":"hemophilia-b","name":"Hemophilia B","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":1,"trial_count":7},"drugs":{"marketed":[{"drug_id":"fitusiran","indication_name":"Hemophilia B","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Qfitlia","generic_name":"FITUSIRAN","company_name":"Genzyme Corp","drug_phase":"marketed","molecular_target":"","drug_class":"Antithrombin-directed RNA Interaction [EPC]","quality_score":10,"revenue":"400","mechanism":"Qfitlia works by using small RNA molecules to block the production of antithrombin, a protein that can interfere with blood clotting."},{"drug_id":"hympavzi","indication_name":"Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A (congenital factor VIII deficiency) without factor VIII inhibitors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hympavzi","generic_name":"Marstacimab-Hncq","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Tissue Factor Pathway Inhibitor (TFPI) Kunitz domain 2 (K2)","drug_class":"Tissue Factor Pathway Inhibitor (TFPI) Antagonist","quality_score":65,"revenue":null,"mechanism":"Monoclonal antibody against TFPI Kunitz domain 2 to neutralize TFPI and enhance coagulation."},{"drug_id":"hympavzi","indication_name":"Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia B (congenital factor IX deficiency) without factor IX inhibitors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hympavzi","generic_name":"Marstacimab-Hncq","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Tissue Factor Pathway Inhibitor (TFPI) Kunitz domain 2 (K2)","drug_class":"Tissue Factor Pathway Inhibitor (TFPI) Antagonist","quality_score":65,"revenue":null,"mechanism":"Monoclonal antibody against TFPI Kunitz domain 2 to neutralize TFPI and enhance coagulation."},{"drug_id":"gbt021601","indication_name":"Treatment of adult patients with severe hemophilia A with inhibitors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gbt021601","generic_name":"gbt021601","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"unknown","quality_score":22,"revenue":null,"mechanism":""},{"drug_id":"pf-07202954-single-dose","indication_name":"Hemophilia A with inhibitors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07202954 Single Dose","generic_name":"pf-07202954-single-dose","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chembl-chembl3990039","indication_name":"hemophilia B (congenital factor IX deficiency)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hympavzi","generic_name":"MARSTACIMAB","company_name":"Pfizer Inc","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Monoclonal Antibody","quality_score":10,"revenue":null,"mechanism":"Hympavzi works by binding to Factor Xa, a protein involved in blood clotting."},{"drug_id":"chembl-chembl3990039","indication_name":"hemophilia B (congenital factor IX deficiency)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hympavzi","generic_name":"MARSTACIMAB","company_name":"Pfizer Inc","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Monoclonal Antibody","quality_score":10,"revenue":null,"mechanism":"Hympavzi works by binding to Factor Xa, a protein involved in blood clotting."},{"drug_id":"concizumab","indication_name":"hemophilia A (congenital factor VIII deficiency) with or without FVIII inhibitors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Alhemo","generic_name":"CONCIZUMAB","company_name":"Novo Nordisk Inc","drug_phase":"marketed","molecular_target":"","drug_class":"Tissue Factor Pathway Inhibitor Antagonist [EPC]","quality_score":52,"revenue":null,"mechanism":"Alhemo works by blocking the activation of blood clotting factors to prevent excessive bleeding in people with hemophilia."},{"drug_id":"concizumab","indication_name":"hemophilia B (congenital factor IX deficiency)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Alhemo","generic_name":"CONCIZUMAB","company_name":"Novo Nordisk Inc","drug_phase":"marketed","molecular_target":"","drug_class":"Tissue Factor Pathway Inhibitor Antagonist [EPC]","quality_score":52,"revenue":null,"mechanism":"Alhemo works by blocking the activation of blood clotting factors to prevent excessive bleeding in people with hemophilia."},{"drug_id":"concizumab","indication_name":"hemophilia B (congenital factor IX deficiency) with or without FIX inhibitors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Alhemo","generic_name":"CONCIZUMAB","company_name":"Novo Nordisk Inc","drug_phase":"marketed","molecular_target":"","drug_class":"Tissue Factor Pathway Inhibitor Antagonist [EPC]","quality_score":52,"revenue":null,"mechanism":"Alhemo works by blocking the activation of blood clotting factors to prevent excessive bleeding in people with hemophilia."}],"pipeline":[{"drug_id":"marstacimab","indication_name":"Hemophilia A or B","indication_type":"pipeline","phase":"preclinical","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Marstacimab","generic_name":"marstacimab","company_name":"Pfizer Inc.","drug_phase":"preclinical","molecular_target":"","drug_class":"For patients aged 12 years or older and weighing at least 35 kg, marstacimab is administered subcuta","quality_score":0,"revenue":null,"mechanism":"Marstacimab blocks a protein that normally prevents blood clotting, allowing patients with hemophilia to form clots more easily."},{"drug_id":"nonacog-alfa-genetical-recombination","indication_name":"Hemophilia B","indication_type":"pipeline","phase":"preclinical","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nonacog Alfa (Genetical Recombination)","generic_name":"nonacog-alfa-genetical-recombination","company_name":"Pfizer Inc.","drug_phase":"preclinical","molecular_target":"","drug_class":"Patients with hemophilia B (congenital blood coagulation factor IX deficiency) who are administered ","quality_score":null,"revenue":null,"mechanism":"Patients with hemophilia B (congenital blood coagulation factor IX deficiency) who are administered "}],"offLabel":[],"totalMarketed":10,"totalPipeline":2},"trials":{"data":[{"nct_id":"NCT06820515","title":"ATHNdataset Registry","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":200000,"lead_sponsor_name":"American Thrombosis and Hemostasis Network","has_results":false},{"nct_id":"NCT03655223","title":"Early Check: Expanded Screening in Newborns","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":30000,"lead_sponsor_name":"RTI International","has_results":false},{"nct_id":"NCT05687474","title":"Baby Detect : Genomic Newborn Screening","phase":"","overall_status":"COMPLETED","enrollment_count":6824,"lead_sponsor_name":"Centre Hospitalier Universitaire de Liege","has_results":false},{"nct_id":"NCT06727669","title":"Longitudinal Cohort of Thrombosis and Hemostasis Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT04645199","title":"National Longitudinal Cohort of Hematological Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":2300,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT03533504","title":"Web Accessible Population Pharmacokinetics Service - Hemophilia: Sources of Variability","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"McMaster University","has_results":false},{"nct_id":"NCT07205523","title":"High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT)","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Yigeng Cao,MD,PhD","has_results":false},{"nct_id":"NCT02912143","title":"German Pediatric Hemophilia Research Database","phase":"","overall_status":"RECRUITING","enrollment_count":800,"lead_sponsor_name":"Goethe University","has_results":false},{"nct_id":"NCT03615053","title":"Personalized Medicine for Canadians With Hemophilia","phase":"NA","overall_status":"UNKNOWN","enrollment_count":600,"lead_sponsor_name":"McMaster University","has_results":false},{"nct_id":"NCT06008938","title":"An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX® in Patients With Hemophilia B","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"CSL Behring","has_results":false},{"nct_id":"NCT06938542","title":"Palliative Care Needs of Children With Rare Diseases and Their Families","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":480,"lead_sponsor_name":"Children's National Research Institute","has_results":false},{"nct_id":"NCT06158334","title":"Study of Surgical Practices in Patients With Haemophilia A or B Treated With an Extended Half-life Recombinant Factor VIII-Fc or IX-Fc (ELOCTA®, ALPROLIX®)","phase":"","overall_status":"UNKNOWN","enrollment_count":400,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT03619863","title":"ATHN 7: Hemophilia Natural History Study","phase":"","overall_status":"COMPLETED","enrollment_count":395,"lead_sponsor_name":"American Thrombosis and Hemostasis Network","has_results":false},{"nct_id":"NCT01154231","title":"BeneFIX Drug Use Results Survey [All-Case Surveillance]","phase":"","overall_status":"COMPLETED","enrollment_count":314,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT03834727","title":"Characterizing the Impact and Treatment of Reproductive Tract Bleeding on Women and Post-menarchal Girls With Bleeding Disorders","phase":"","overall_status":"COMPLETED","enrollment_count":256,"lead_sponsor_name":"Oregon Health and Science University","has_results":false},{"nct_id":"NCT05145127","title":"Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":245,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT03185897","title":"Global Epidemiologic Study of Preexisting Immunity to AAV in Adults With Severe Hemophilia","phase":"","overall_status":"COMPLETED","enrollment_count":242,"lead_sponsor_name":"Baxalta now part of Shire","has_results":false},{"nct_id":"NCT03818529","title":"ATHN 8: Previously Untreated Patients (PUPs) Matter Study","phase":"","overall_status":"COMPLETED","enrollment_count":237,"lead_sponsor_name":"American Thrombosis and Hemostasis Network","has_results":false},{"nct_id":"NCT03587116","title":"A Study to Evaluate Prospective Efficacy and Safety Data of Current FIX Prophylaxis Replacement Therapy in Adult Hemophilia B Subjects (FIX:C≤2%) or Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Subjects (FVIII:C≤1%)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":212,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT07101224","title":"Data Registry in Chinese Hemophilia A and B Patients","phase":"","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT05187936","title":"Pre-clinical Models for Mesenchymal Stem Cell Therapy in Hemophilic Arthropathy","phase":"","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"University Hospital, Montpellier","has_results":false},{"nct_id":"NCT03938792","title":"Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":189,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT04731701","title":"Psychometric Validation of the Hemophilia Functional Ability Scoring Tool (Hemo-FAST)","phase":"","overall_status":"COMPLETED","enrollment_count":180,"lead_sponsor_name":"Swedish Orphan Biovitrum","has_results":false},{"nct_id":"NCT05568719","title":"Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":173,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT03901755","title":"An International Study to Evaluate the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia B","phase":"","overall_status":"COMPLETED","enrollment_count":151,"lead_sponsor_name":"Swedish Orphan Biovitrum","has_results":false},{"nct_id":"NCT05044845","title":"Needs Assessment of Knowledge, Beliefs, and Attitudes of Patients With Hemophilia B About Gene Therapy","phase":"","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"St. Jude Children's Research Hospital","has_results":false},{"nct_id":"NCT06379789","title":"A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":130,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT06569108","title":"Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B Without Inhibitors","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":125,"lead_sponsor_name":"Suzhou Alphamab Co., Ltd.","has_results":false},{"nct_id":"NCT03417245","title":"A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without Inhibitors","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":120,"lead_sponsor_name":"Genzyme, a Sanofi Company","has_results":true},{"nct_id":"NCT01286779","title":"BAX 326 (rFIX) Continuation Study","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":117,"lead_sponsor_name":"Baxalta now part of Shire","has_results":true},{"nct_id":"NCT06864975","title":"Assessing Different FVIII Doses and Frequencies in Immune Tolerance Induction (ITI) with ADVATE Among Hemophilia a Boys with Inhibitor (INITIATE Study)","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":110,"lead_sponsor_name":"Runhui WU","has_results":false},{"nct_id":"NCT07096349","title":"Multidimensional Assessment of Chronic Pain in Severe Haemophilia A","phase":"","overall_status":"RECRUITING","enrollment_count":109,"lead_sponsor_name":"Investigación en Hemofilia y Fisioterapia","has_results":false},{"nct_id":"NCT05605678","title":"Hemophilia Non-Interventional Study Prior to SerpinPC Intervention (PRESent-5)","phase":"","overall_status":"TERMINATED","enrollment_count":108,"lead_sponsor_name":"ApcinteX Ltd","has_results":false},{"nct_id":"NCT05606640","title":"Gaining Insight Into the Complexity of Pain in Patients With Haemophilia","phase":"","overall_status":"COMPLETED","enrollment_count":104,"lead_sponsor_name":"Universiteit Antwerpen","has_results":false},{"nct_id":"NCT05439642","title":"Validation and Reliability of the CHO-KLAT in Turkish","phase":"NA","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Yuzuncu Yil University","has_results":false},{"nct_id":"NCT05611801","title":"A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT04106323","title":"A Study of Factor Inhibitors in Adult Patients With Hemophilia and Von Willebrand's Disease in Upper Egypt","phase":"","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Safaa AA Khaled","has_results":false},{"nct_id":"NCT02053792","title":"A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":97,"lead_sponsor_name":"CSL Behring","has_results":true},{"nct_id":"NCT02740413","title":"Treatment Patterns And Outcomes In Patients Treated With Benefix Or Refacto/Refacto AF - A Swedish Cohort Study","phase":"","overall_status":"COMPLETED","enrollment_count":86,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT04055051","title":"ATHN 11: Liver Transplantation Outcomes Study","phase":"","overall_status":"COMPLETED","enrollment_count":86,"lead_sponsor_name":"American Thrombosis and Hemostasis Network","has_results":false},{"nct_id":"NCT01174446","title":"Pivotal Study (Pharmacokinetics, Efficacy, Safety) of BAX 326 (rFIX) in Hemophilia B Patients","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":86,"lead_sponsor_name":"Baxalta now part of Shire","has_results":true},{"nct_id":"NCT03569891","title":"HOPE-B: Trial of AMT-061 in Severe or Moderately Severe Hemophilia B Patients","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":67,"lead_sponsor_name":"CSL Behring","has_results":true},{"nct_id":"NCT02190149","title":"Study of Prophylaxis, ACtivity and Effectiveness (SPACE) in Hemophilia Patients Currently Treated With ADVATE or RIXUBIS","phase":"","overall_status":"COMPLETED","enrollment_count":64,"lead_sponsor_name":"Baxalta now part of Shire","has_results":false},{"nct_id":"NCT05980377","title":"Patterns of Hemophilia Care in Assiut Children Patients","phase":"","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"Assiut University","has_results":false},{"nct_id":"NCT05789524","title":"The Efficacy and Safety of SerpinPC in Participants with Severe Hemophilia a or Moderately Severe to Severe Hemophilia B","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":60,"lead_sponsor_name":"ApcinteX Ltd","has_results":false},{"nct_id":"NCT03417102","title":"A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With Inhibitors","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Genzyme, a Sanofi Company","has_results":true},{"nct_id":"NCT02922231","title":"Post-Marketing Surveillance (Usage Results Study) of RIXUBIS in Adult and Pediatric Patients With Haemophilia B in South Korea","phase":"","overall_status":"COMPLETED","enrollment_count":57,"lead_sponsor_name":"Baxalta now part of Shire","has_results":false},{"nct_id":"NCT01128881","title":"IMMUNINE Pre-Treatment Study","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":57,"lead_sponsor_name":"Baxalta now part of Shire","has_results":false},{"nct_id":"NCT05962398","title":"Long-term Follow-up Study of Male Adults With Hemophilia B Previously Treated With Etranacogene Dezaparvovec (CSL222)","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":56,"lead_sponsor_name":"CSL Behring","has_results":false},{"nct_id":"NCT04647227","title":"SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":55,"lead_sponsor_name":"American Thrombosis and Hemostasis Network","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}